Skip to main content
Daniel Kuritzkes, MD, Infectious Disease, Boston, MA, Brigham and Women's Hospital

DanielRobertKuritzkesMD

Infectious Disease • Boston, MA

Professor of Medicine, Brigham and Women's Hospital

Join to view full profile

Dr. Kuritzkes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kuritzkes' full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School
    Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1989 - 1990
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1987 - 1989
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1983 - 1986
  • Harvard Medical School
    Harvard Medical SchoolClass of 1983

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1984 - 2025
  • CO State Medical License
    CO State Medical License 1990 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies  
    Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
  • Targeted HIV Testing at Birth Supported by Low and Predictable Mother‐to‐Child Transmission Risk in Botswana  
    Daniel Kuritzkes, MD, Journal of the International AIDS Society

Authored Content

  • Hematopoietic Stem Cell Transplantation for HIV CureJanuary 2016

Press Mentions

  • Massachusetts' COVID Emergency Ends Thursday: What It Means for You
    Massachusetts' COVID Emergency Ends Thursday: What It Means for YouMay 8th, 2023
  • Individualizing HIV ART: Considerations for Weight Gain
    Individualizing HIV ART: Considerations for Weight GainApril 24th, 2023
  • Individualizing HIV ART: Rapid Start
    Individualizing HIV ART: Rapid StartApril 13th, 2023
  • Join now to see all

Grant Support

  • Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CtuNational Institute Of Allergy And Infectious Diseases2007–2012
  • AIDS Clinical Trials Group NetworkNational Institute Of Allergy And Infectious Diseases2011
  • HIV-1 Resistance To Chemokine Receptor AntagonistsNational Institute Of Allergy And Infectious Diseases2007–2011
  • AIDS Clinical Trials Group NetworkNational Institute Of Allergy And Infectious Diseases2010
  • V3 Loop Characterization By Ultradeep Sequencing During CCR5 Antagonist TherapyNational Institute Of Allergy And Infectious Diseases2009–2010
  • HIV-1 Therapeutics And Drug ResistanceNational Center For Research Resources2002–2010
  • A Phase IV Study Of Antiretroviral Therapy For Hiv-Infected AdultsNational Center For Research Resources2006
  • Fitness Of Enfuvirtide-(T-20)-Resistant HIV-1National Institute Of Allergy And Infectious Diseases2003–2006
  • AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2003–2006
  • HIV-1 Resistance To Nucleoside AnaloguesNational Institute Of Allergy And Infectious Diseases2002–2004
  • Viracept And Sustiva For Treatment Of HIV-1National Center For Research Resources2000–2002
  • Phase I Trial Of T-1249 In HIV Infected AdultsNational Center For Research Resources2000–2002
  • Actg370 Lamivudine VS Delavirdine In 3TC Experienced SubjectsNational Center For Research Resources1998–2002
  • Actg364 Efficacy Of Nelfinavir AND/OR DMP 266 With Nucleoside AnalogsNational Center For Research Resources1998–2002
  • HIV-1 Resistance To Nucleoside AnaloguesNational Institute Of Allergy And Infectious Diseases2001
  • HIV-1 Therapeutics And Drug ResistanceNational Center For Research Resources2001
  • PNU 140690 Dose Escalation--Eval Tolerance Pharmacokinetics Eff In HIVNational Center For Research Resources1999–2000
  • HIV-1 Dual Resistance To AZT And 3TCNational Institute Of Allergy And Infectious Diseases1998–2000
  • Pharmacokinetics Of Indinavir SulfateNational Center For Research Resources1998–1999
  • Hiv-1-Specific Ctls In Perinatally Exposed ChildrenNational Institute Of Allergy And Infectious Diseases1993–1997
  • ACTG 251--Thalidomide Treatment For Oral/Esophageal Aphthous UlcersNational Center For Research Resources1996
  • ACTG 242--Amytryptilene/Mexiletine For HIV NeuropathyNational Center For Research Resources1996
  • Thalidomide Treatment For Oral/Esophageal Aphthous Ulcers + HIV ViremiaNational Center For Research Resources1995
  • Evaluation Of Antiviral Effects Of RibozymesNational Institute Of Allergy And Infectious Diseases1994–1995
  • HIV Epitopes Recognized By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1990–1993
  • Functional Domains Of HTLV Envelope ProteinsNational Center For Research Resources1991
  • HIV Epitopes Recognized By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1989–1990

Hospital Affiliations

Dr. Daniel Kuritzkes, Dr. Daniel Kuritzkes, MD, Dr. D Kuritzkes, Dr. Daniel Robert Kuritzkes